Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale
Open Access
- 9 July 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (43), 3362-3369
- https://doi.org/10.1093/eurheartj/eht283
Abstract
Percutaneous patent foramen ovale (PFO) closure for secondary stroke prevention is discussed controversially. Long-term data comparing different closure devices are limited. The objective is the prospective comparison of procedural complications and long-term results after PFO closure in patients with cryptogenic stroke randomized to three different closure devices. Between January 2001 and December 2004, 660 patients with cryptogenic stroke were randomized to three different closure devices (Amplatzer, CardioSEAL-STARflex, and Helex occluder, 220 patients per group). The primary endpoint was defined as recurrent cerebral ischaemia [stroke, transient ischaemic attacks (TIA), or Amaurosis fugax], death from neurological cause, or any other paradoxical embolism within 5 years after the index procedure. Device implantation was technically successful in all interventions (n = 660; 100%). The procedure was complicated by pericardial tamponade requiring surgery in one patient (Amplatzer group) and device embolization in three patients (all Helex group). Thrombus formation on the device was detected in 12 cases (11 CardioSEALSTARflex, 1 Helex, 0 Amplatzer; P < 0.0001), of which 2 required surgery. Complete closure after single device implantation was more common with the Amplatzer and with the CardioSEAL-STARflex than with the Helex occluder: Amplatzer vs. Helex vs. CardioSEAL-STARflex: n = 217 (98.6%) vs. n = 202 (91.8%) vs. n = 213 (96.8%; P = 0.0012). Within 5 years of follow-up, the primary endpoint occurred in 25 patients (3.8%; 10 TIAs, 12 strokes and 3 cases of cerebral death). Compared with the CardioSEAL-STARflex (6%; 6 TIAs, 6 strokes, 1 cerebral death) and Helex groups (4%; 4 TIAs, 4 stroke, 1 cerebral death), significantly fewer events (P = 0.04) occurred in the Amplatzer group (1.4%; 2 strokes, 1 cerebral death). Although procedural complications and long-term neurological event rates are low regardless of the device used, the recurrent neurological event rate was significantly lower after Amplatzer than after CardioSEAL-STARflex or Helex implantation. This has important implications regarding the interpretation of trials comparing PFO closure with medical management.Keywords
This publication has 21 references indexed in Scilit:
- Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic StrokeThe New England Journal of Medicine, 2013
- Percutaneous Closure of Patent Foramen Ovale in Cryptogenic EmbolismThe New England Journal of Medicine, 2013
- Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen OvaleThe New England Journal of Medicine, 2012
- Thrombus in transit within a patent foramen ovale: An argument for consideration of prophylactic closure?Journal of Clinical Ultrasound, 2011
- Interatrial thrombus-in-transit resulting in paradoxical thromboembolismJournal of Thrombosis and Thrombolysis, 2009
- Comparison of Three Patent Foramen Ovale Closure Devices in a Randomized Trial (Amplatzer Versus CardioSEAL-STARflex Versus Helex Occluder)The American Journal of Cardiology, 2008
- Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolismHeart, 2008
- Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic strokeJournal of the American College of Cardiology, 2004
- Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism Periprocedural safety and mid-term follow-up results of three different device occluder systemsPublished by Oxford University Press (OUP) ,2004
- Prevalence of Patent Foramen Ovale in Patients with StrokeNew England Journal of Medicine, 1988